Raynaud F - Search Results

1

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, Box G, Ortiz-Ruiz MJ, Valenti M, De Haven Brandon A, TePoele R, Leuthner B, Workman P, Aherne W, Poeschke O, Dale T, Wienke D, Esdar C, Rohdich F, Raynaud F, Clarke PA, Eccles SA, Stieber F, Schiemann K, Blagg J. Mallinger A, et al. Among authors: raynaud f. J Med Chem. 2015 Feb 26;58(4):1717-35. doi: 10.1021/jm501436m. Epub 2015 Feb 13. J Med Chem. 2015. PMID: 25680029 Free PMC article.

2

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Waters JS, et al. Among authors: raynaud f. J Clin Oncol. 2000 May;18(9):1812-23. doi: 10.1200/JCO.2000.18.9.1812. J Clin Oncol. 2000. PMID: 10784621 Clinical Trial.

3

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

Smith V, Raynaud F, Workman P, Kelland LR. Smith V, et al. Among authors: raynaud f. Mol Pharmacol. 2001 Nov;60(5):885-93. doi: 10.1124/mol.60.5.885. Mol Pharmacol. 2001. PMID: 11641415

4

Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.

Rogers PM, Beale PJ, Al-Moundhri M, Boxall F, Patterson L, Valenti M, Raynaud F, Hobbs S, Johnston S, Kelland LR. Rogers PM, et al. Among authors: raynaud f. Int J Cancer. 2002 Feb 20;97(6):858-63. doi: 10.1002/ijc.10132. Int J Cancer. 2002. PMID: 11857368 Free article.

5

Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.

Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Seddon BM, et al. Among authors: raynaud f. Clin Cancer Res. 2002 Jul;8(7):2323-35. Clin Cancer Res. 2002. PMID: 12114437

6

Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Raynaud FI, et al. Mol Cancer Ther. 2004 Mar;3(3):353-62. Mol Cancer Ther. 2004. PMID: 15026556

7

Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.

Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. Spruce BA, et al. Among authors: raynaud f. Cancer Res. 2004 Jul 15;64(14):4875-86. doi: 10.1158/0008-5472.CAN-03-3180. Cancer Res. 2004. PMID: 15256458

8

Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.

Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P. Smith NF, et al. Among authors: raynaud fi. Cancer Chemother Pharmacol. 2004 Dec;54(6):475-86. doi: 10.1007/s00280-004-0853-7. Epub 2004 Jul 29. Cancer Chemother Pharmacol. 2004. PMID: 15526201

9

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P. Nutley BP, et al. Mol Cancer Ther. 2005 Jan;4(1):125-39. Mol Cancer Ther. 2005. PMID: 15657360

10

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P. Raynaud FI, et al. Clin Cancer Res. 2005 Jul 1;11(13):4875-87. doi: 10.1158/1078-0432.CCR-04-2264. Clin Cancer Res. 2005. PMID: 16000586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

340 results

Search Page